{"name":"Versameb","slug":"versameb","ticker":"Private","exchange":"Private","domain":"versameb.com","description":"Versameb is a private pharmaceutical company focused on mRNA gene therapy and rare diseases. The company has a pipeline of innovative treatments for various indications. With a strong focus on research and development, Versameb aims to bring life-changing therapies to patients worldwide. As a private company, Versameb does not publicly disclose its financials, but its pipeline and partnerships suggest significant growth potential.","hq":"Frankfurt, Germany","founded":0,"employees":"","ceo":"Christian Cobaugh","sector":"mRNA Gene Therapy / Rare Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$250M (est. last round)","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"VMB-101 patent cliff ($100M at risk)","drug":"VMB-101","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"VMB-102 patent cliff ($50M at risk)","drug":"VMB-102","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"Versameb Receives FDA Orphan Drug Designation for VMB-101","summary":"The FDA granted orphan drug designation to VMB-101, a treatment for a rare genetic disorder.","drugName":"VMB-101","sentiment":"positive"},{"date":"2023-11-01","type":"deal","headline":"Versameb Partners with Biogen to Develop mRNA Therapies for Neurological Disorders","summary":"Versameb partnered with Biogen to develop mRNA therapies for neurological disorders, expanding its pipeline and capabilities.","drugName":"","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"VMB-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000},{"drugName":"VMB-102","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":50000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Moderna Therapeutics","BioNTech","Pfizer"],"therapeuticFocus":["mRNA Gene Therapy","Rare Diseases"],"financials":null,"yahoo":null}